Q9TTR7
PR
Gene name |
NR2F2 (TFCOUP2) |
Protein name |
COUP transcription factor 2 |
Names |
COUP-TF2, COUP transcription factor II, COUP-TF II, Nuclear receptor subfamily 2 group F member 2 |
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:281945 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q9TTR7
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q9TTR7-F1 | Predicted | AlphaFoldDB |
100 variants for Q9TTR7
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs137384129 | 5 | V>G | No | EVA | |
| rs450645060 | 50 | S>R | No | EVA | |
| rs467349425 | 50 | S>T | No | EVA | |
| rs481883972 | 52 | P>R | No | EVA | |
| rs463163269 | 53 | A>G | No | EVA | |
| rs446217708 | 55 | T>K | No | EVA | |
| rs477655443 | 56 | A>G | No | EVA | |
| rs440677253 | 57 | A>D | No | EVA | |
| rs460892005 | 57 | A>S | No | EVA | |
| rs461154577 | 58 | G>S | No | EVA | |
| rs475668297 | 65 | G>R | No | EVA | |
| rs452193573 | 66 | P>A | No | EVA | |
| rs473171992 | 69 | D>A | No | EVA | |
| rs473171992 | 69 | D>G | No | EVA | |
| rs453212123 | 71 | Q>* | No | EVA | |
| rs436262103 | 71 | Q>R | No | EVA | |
| rs467387975 | 75 | Q>H | No | EVA | |
| rs456888311 | 77 | I>S | No | EVA | |
| rs436895165 | 79 | C>G | No | EVA | |
| rs465113408 | 81 | V>G | No | EVA | |
| rs444884434 | 82 | C>G | No | EVA | |
| rs467117597 | 94 | F>I | No | EVA | |
| rs447159150 | 106 | S>R | No | EVA | |
| rs481737758 | 109 | R>T | No | EVA | |
| rs444350896 | 124 | D>G | No | EVA | |
| rs482020659 | 125 | Q>L | No | EVA | |
| rs458918541 | 126 | H>P | No | EVA | |
| rs438866466 | 129 | N>T | No | EVA | |
| rs473256811 | 141 | K>R | No | EVA | |
| rs442722784 | 142 | V>A | No | EVA | |
| rs452998161 | 142 | V>L | No | EVA | |
| rs472202881 | 149 | V>G | No | EVA | |
| rs441073357 | 149 | V>L | No | EVA | |
| rs461549143 | 150 | Q>* | No | EVA | |
| rs441682052 | 151 | R>G | No | EVA | |
| rs476071723 | 151 | R>S | No | EVA | |
| rs456074436 | 152 | G>D | No | EVA | |
| rs472007985 | 153 | R>W | No | EVA | |
| rs435050785 | 154 | M>R | No | EVA | |
| rs451938201 | 154 | M>V | No | EVA | |
| rs466143199 | 155 | P>Q | No | EVA | |
| rs435682693 | 158 | Q>H | No | EVA | |
| rs470323752 | 164 | F>V | No | EVA | |
| rs478086887 | 167 | T>P | No | EVA | |
| rs447511842 | 173 | N>K | No | EVA | |
| rs464339292 | 173 | N>T | No | EVA | |
| rs478920171 | 180 | G>V | No | EVA | |
| rs441519022 | 196 | F>V | No | EVA | |
| rs482416749 | 197 | G>R | No | EVA | |
| rs462518445 | 199 | Q>L | No | EVA | |
| rs439266084 | 202 | Q>E | No | EVA | |
| rs471998042 | 202 | Q>R | No | EVA | |
| rs451848585 | 203 | P>R | No | EVA | |
| rs441503896 | 204 | N>D | No | EVA | |
| rs456024519 | 219 | M>T | No | EVA | |
| rs435618673 | 221 | F>C | No | EVA | |
| rs456653044 | 224 | V>G | No | EVA | |
| rs433241389 | 226 | W>G | No | EVA | |
| rs464339734 | 237 | Q>R | No | EVA | |
| rs447399107 | 239 | T>P | No | EVA | |
| rs478951390 | 240 | D>A | No | EVA | |
| rs468350617 | 247 | L>P | No | EVA | |
| rs448276344 | 251 | E>* | No | EVA | |
| rs482453561 | 251 | E>A | No | EVA | |
| rs477101174 | 256 | N>T | No | EVA | |
| rs458280289 | 259 | Q>E | No | EVA | |
| rs441451331 | 261 | S>P | No | EVA | |
| rs472776711 | 265 | H>P | No | EVA | |
| rs462478402 | 269 | L>P | No | EVA | |
| rs442318543 | 274 | G>V | No | EVA | |
| rs476621560 | 280 | M>L | No | EVA | |
| rs471059857 | 286 | V>A | No | EVA | |
| rs433282075 | 286 | V>F | No | EVA | |
| rs454137486 | 291 | H>P | No | EVA | |
| rs431927022 | 297 | E>D | No | EVA | |
| rs468185345 | 299 | V>G | No | EVA | |
| rs468818895 | 313 | S>R | No | EVA | |
| rs445581063 | 315 | L>P | No | EVA | |
| rs467611165 | 324 | D>V | No | EVA | |
| rs482266909 | 326 | C>S | No | EVA | |
| rs459022653 | 326 | C>W | No | EVA | |
| rs445311223 | 327 | G>V | No | EVA | |
| rs459508909 | 328 | L>F | No | EVA | |
| rs463648289 | 329 | S>F | No | EVA | |
| rs474045895 | 329 | S>P | No | EVA | |
| rs443241197 | 330 | D>A | No | EVA | |
| rs443241197 | 330 | D>V | No | EVA | |
| rs434450830 | 331 | V>A | No | EVA | |
| rs451323578 | 331 | V>L | No | EVA | |
| rs473418656 | 332 | A>P | No | EVA | |
| rs453339901 | 333 | H>L | No | EVA | |
| rs453339901 | 333 | H>P | No | EVA | |
| rs436658384 | 334 | V>G | No | EVA | |
| rs467954046 | 336 | S>I | No | EVA | |
| rs457630867 | 336 | S>R | No | EVA | |
| rs465348988 | 343 | C>W | No | EVA | |
| rs445308237 | 359 | R>G | No | EVA | |
| rs479869920 | 368 | P>L | No | EVA | |
| rs449147621 | 414 | Q>K | No | EVA | |
| rs480405876 | 414 | Q>R | No | EVA |
No associated diseases with Q9TTR7
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
5 GO annotations of molecular function
| Name | Definition |
|---|---|
| nuclear receptor activity | A DNA-binding transcription factor activity regulated by binding to a ligand that modulates the transcription of specific gene sets transcribed by RNA polymerase II. Nuclear receptor ligands are usually lipid-based (such as a steroid hormone) and the binding of the ligand to its receptor often occurs in the cytoplasm, which leads to its tranlocation to the nucleus. |
| protein homodimerization activity | Binding to an identical protein to form a homodimer. |
| retinoic acid binding | Binding to retinoic acid, 3,7-dimethyl-9-(2,6,-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid. |
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II. |
| zinc ion binding | Binding to a zinc ion (Zn). |
21 GO annotations of biological process
| Name | Definition |
|---|---|
| anatomical structure development | The biological process whose specific outcome is the progression of an anatomical structure from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure, whatever form that may be including its natural destruction. An anatomical structure is any biological entity that occupies space and is distinguished from its surroundings. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome. |
| anterior/posterior pattern specification | The regionalization process in which specific areas of cell differentiation are determined along the anterior-posterior axis. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism. |
| blood vessel morphogenesis | The process in which the anatomical structures of blood vessels are generated and organized. The blood vessel is the vasculature carrying blood. |
| cell differentiation | The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state. |
| female gonad development | The process whose specific outcome is the progression of the female gonad over time, from its formation to the mature structure. |
| fertilization | The union of gametes of opposite sexes during the process of sexual reproduction to form a zygote. It involves the fusion of the gametic nuclei (karyogamy) and cytoplasm (plasmogamy). |
| forebrain development | The process whose specific outcome is the progression of the forebrain over time, from its formation to the mature structure. The forebrain is the anterior of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main control center for sensory and associative information processing, visceral functions, and voluntary motor functions). |
| interneuron migration | The orderly movement of an interneuron from one site to another. |
| lymphatic endothelial cell fate commitment | The commitment of a venous blood vessel endothelial cell to a lymphatic endothelial cell fate and its capacity to differentiate into a lymphatic endothelial cell. |
| maternal placenta development | Maternally driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
| negative regulation of cyclin-dependent protein serine/threonine kinase activity | Any process that stops, prevents, or reduces the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity. |
| negative regulation of endothelial cell migration | Any process that decreases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. |
| negative regulation of endothelial cell proliferation | Any process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation. |
| negative regulation of transcription by RNA polymerase II | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| placenta blood vessel development | The process whose specific outcome is the progression of a blood vessel of the placenta over time, from its formation to the mature structure. |
| positive regulation of DNA-templated transcription | Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| radial pattern formation | The regionalization process that results in defined areas around a point in which specific types of cell differentiation will occur. |
| regulation of transcription by RNA polymerase II | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| skeletal muscle tissue development | The developmental sequence of events leading to the formation of adult skeletal muscle tissue. The main events are: the fusion of myoblasts to form myotubes that increase in size by further fusion to them of myoblasts, the formation of myofibrils within their cytoplasm and the establishment of functional neuromuscular junctions with motor neurons. At this stage they can be regarded as mature muscle fibers. |
| trophoblast giant cell differentiation | The process in which a relatively unspecialized cell acquires specialized features of a trophoblast giant cell of the placenta. Trophoblast giant cells are the cell of the placenta that line the maternal decidua. |
28 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| O18971 | PPARG | Peroxisome proliferator-activated receptor gamma | Bos taurus (Bovine) | PR |
| P68306 | THRB | Thyroid hormone receptor beta | Gallus gallus (Chicken) | PR |
| Q90733 | NR2F2 | COUP transcription factor 2 | Gallus gallus (Chicken) | PR |
| A7X8B3 | PGR | Progesterone receptor | Pan troglodytes (Chimpanzee) | SS |
| P37231 | PPARG | Peroxisome proliferator-activated receptor gamma | Homo sapiens (Human) | PR |
| P10588 | NR2F6 | Nuclear receptor subfamily 2 group F member 6 | Homo sapiens (Human) | PR |
| P06401 | PGR | Progesterone receptor | Homo sapiens (Human) | EV |
| P10589 | NR2F1 | COUP transcription factor 1 | Homo sapiens (Human) | PR |
| O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (Human) | PR |
| P49116 | NR2C2 | Nuclear receptor subfamily 2 group C member 2 | Homo sapiens (Human) | PR |
| P24468 | NR2F2 | COUP transcription factor 2 | Homo sapiens (Human) | PR |
| P35396 | Ppard | Peroxisome proliferator-activated receptor delta | Mus musculus (Mouse) | PR |
| P43136 | Nr2f6 | Nuclear receptor subfamily 2 group F member 6 | Mus musculus (Mouse) | PR |
| Q00175 | Pgr | Progesterone receptor | Mus musculus (Mouse) | SS |
| Q9Z0Y9 | Nr1h3 | Oxysterols receptor LXR-alpha | Mus musculus (Mouse) | PR |
| P43135 | Nr2f2 | COUP transcription factor 2 | Mus musculus (Mouse) | PR |
| O62807 | PPARG | Peroxisome proliferator-activated receptor gamma | Sus scrofa (Pig) | PR |
| Q63449 | Pgr | Progesterone receptor | Rattus norvegicus (Rat) | SS |
| O09018 | Nr2f2 | COUP transcription factor 2 | Rattus norvegicus (Rat) | PR |
| Q8SQ01 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Macaca mulatta (Rhesus macaque) | PR |
| G5EFF5 | daf-12 | Nuclear hormone receptor family member daf-12 | Caenorhabditis elegans | PR |
| O45460 | nhr-54 | Nuclear hormone receptor family member nhr-54 | Caenorhabditis elegans | PR |
| Q20765 | nhr-7 | Nuclear hormone receptor family member nhr-7 | Caenorhabditis elegans | PR |
| Q21006 | nhr-34 | Nuclear hormone receptor family member nhr-34 | Caenorhabditis elegans | PR |
| O17928 | nhr-52 | Nuclear hormone receptor family member nhr-52 | Caenorhabditis elegans | PR |
| Q21878 | nhr-1 | Nuclear hormone receptor family member nhr-1 | Caenorhabditis elegans | PR |
| O18141 | nhr-79 | Nuclear hormone receptor family member nhr-79 | Caenorhabditis elegans | PR |
| Q6PH18 | nr2f1b | Nuclear receptor subfamily 2 group F member 1-B | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAMVVSTWRD | PQDEVPGSQG | SQASQAPPVP | GPPPGAPHTP | QTPGQGGPAS | TPAQTAAGGQ |
| 70 | 80 | 90 | 100 | 110 | 120 |
| GGPGGPGSDK | QQQQQHIECV | VCGDKSSGKH | YGQFTCEGCK | SFFKRSVRRN | LSYTCRANRN |
| 130 | 140 | 150 | 160 | 170 | 180 |
| CPIDQHHRNQ | CQYCRLKKCL | KVGMRREAVQ | RGRMPPTQPS | HGQFALTNGD | PLNCHSYLSG |
| 190 | 200 | 210 | 220 | 230 | 240 |
| YISLLLRAEP | YPTSRFGSQC | MQPNNIMGIE | NICELAARML | FSAVEWARNI | PFFPDLQITD |
| 250 | 260 | 270 | 280 | 290 | 300 |
| QVALLRLTWS | ELFVLNAAQC | SMPLHVAPLL | AAAGLHASPM | SADRVVAFMD | HIRIFQEQVE |
| 310 | 320 | 330 | 340 | 350 | 360 |
| KLKALHVDSA | EYSCLKAIVL | FTSDACGLSD | VAHVESLQEK | SQCALEEYVR | SQYPNQPTRF |
| 370 | 380 | 390 | 400 | 410 | |
| GKLLLRLPSL | RTVSSSVIEQ | LFFVRLVGKT | PIETLIRDML | LSGSSFNWPY | MAIQ |